The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
|Articles|January 6, 2003
Cover Story: COMPOUNDING UNDER SIEGE
The practice of compounding medications is under seige by critics both inside and outside the profession due to large-scale production bordering on manufacturing and the illness and death of patients from contaminated drugs.
Advertisement
Advertisement
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
2
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
3
Menopause Status, Symptoms Remain Inconsistently Documented
4
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
5